Evommune is a private, R&D company and innovation engine in chronic inflammation. Evommune is taking a tissue-based approach to advance insights and accelerate the development of transformative medicines in inflammatory diseases. Evommune was founded in 2020 by a successful and experienced leadership team focused on building a robust pipeline of unique therapies that help patients with chronic inflammatory diseases. The company is headquartered in Los Altos, California.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/18/20 | $12,000,000 | Seed |
Pivotal bioVenture Partners | undisclosed |
| 11/05/24 | $115,000,000 | Series C |
ADAR1 Partners Allostery Investments Amplitude Ventures Andera Partners Avego Bioscience Capital B Capital Beiersdorf Venture Capital EQT Life Sciences FemHealth Ventures Longwood Fund Marshall Wace NEXTBio Capital Pivotal bioVenture Partners RA Capital Management  RTW Investments Sectoral Asset Management Symbiosis | undisclosed |
